Kai Xu

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 1

Top Topics

Radiation Therapy

Ejection Fraction

Prognostic Factors

Decision Making

Top Venues

International journal of clinical pharmacy

This page only lists publications with an associated author ORCID identifier.

Publications

Jingxuan Wei, Kai Xu, Ying-Tao Lin, Qiang Liu, Chongchong Zhou, Pei Zhang, Rui Ma, Mengdie Zhang, Lingli Zhang, Xin Li
Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China. International journal of clinical pharmacy (2024)